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Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant role 
starting in the early phases of cancer progression. This event occurs in a three-dimensional (3D) 
environment, which to date, has been difficult to reproduce in vitro due to its complexity. While bi-
dimensional cultures have generated substantial data, there is a progressive awareness that 3D culture 
strategies may rapidly increase the understanding of tumor development and be used in anti-cancer 
compound screening and for predicting response to new drugs utilizing personalized approaches. 
However, simple systems capable of rapidly rebuilding cancer tissues ex-vivo in 3D are needed and 
could be used for a variety of applications. Therefore, we developed a flat, handheld and versatile 3D 
cell culture bioreactor that can be loaded with tumor and/or normal cells in combination which can be 
monitored using a variety of read-outs. This biocompatible device sustained 3D growth of tumor cell 
lines representative of various cancers, such as pancreatic and breast adenocarcinoma, sarcoma, and 
glioblastoma. The cells repopulated the thin matrix which was completely separated from the outer 
space by two gas-permeable membranes and was monitored in real-time using both microscopy and 
luminometry, even after transportation. The device was tested in 3D cytotoxicity assays to investigate 
the anti-cancer potential of chemotherapy, biologic agents, and cell-based therapy in co-cultures. The 
addition of luciferase in target cancer cells is suitable for comparative studies that may also involve 
parallel in vivo investigations. Notably, the system was challenged using primary tumor cells harvested 
from lung cancer patients as an innovative predictive functional assay for cancer responsiveness to 
checkpoint inhibitors, such as nivolumab. This bioreactor has several novel features in the 3D-culture 
field of research, representing a valid tool useful for cancer investigations, drug screenings, and other 
toxicology approaches.
The interest in three-dimensional (3D) cell culture models is constantly increasing due to the recognized advan-
tages of 3D in vitro growth compared with the traditional two-dimensional (2D) monolayer cell cultures1,2.
3D models can mimic in vivo cellular behavior providing more physiologically relevant information on cell 
growth and responses to a variety of chemical, physical, and immunological stimuli3,4. The pharmaceutical indus-
try is one of the most relevant field requiring breakthrough 3D technologies to fill possible gaps between in silico 
hypotheses/in vitro results and the in vivo settings4. Although high throughput technologies offer the possibility 
to screen large amounts of putative drugs, the research and development of physiologically relevant compounds 
still require in vivo testing before progressing towards clinical studies5.
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In addition to increasing ethical concerns, animal studies may be cumbersome and not always reproduce 
human diseases, thus, alternative or at least complementary pre-clinical tools are needed6,7. This is particularly 
true for the research on new anti-cancer compounds requiring complex interactions between different cell types 
such as cancer and immune cells that may be extremely difficult to reproduce during animal investigations8. 
Furthermore, alternative tests to rapidly predict anti-cancer actions are needed to reduce the relevant attrition 
rate during drug development9–11.
3D tumor cultures are a promising tool for in vitro rebuilding the in vivo behavior of cancer cells for the 
development and validation of anti-tumor therapies. Various 3D cell culture technologies have been created to 
better represent in vivo biology, however, advantages and limitations exist12–14. Therefore, we developed a novel 
3D culture system as a tool that contributes to bridge in vitro and in vivo studies. This tool, named VITVO, is a 
small flat bioreactor that can rapidly recreate in vitro an in vivo-like environment to host a variety of normal and 
pathological cells in a 3D manner within a completely closed environment. Herein, the use of VITVO in several 
assays focusing on oncology is reported and the efficacy of chemotherapy, biologics, and cell-based anti-cancer 
agents was tested by comparing VITVO with an in vivo preclinical xenotransplant model. The flexibility offered 
by this novel platform within the different approaches indicates the potential of VITVO as an innovative 3D in 
vitro model for preclinical testing.
Results
The 3D bioreactor: structure and potential. VITVO is a small and portable bioreactor developed to 
recreate a 3D tissue-like structure in a closed system that is easy to study and monitor over time (Fig. 1a). The bio-
reactor is formed by a perimetral frame continuous with two optical transparent oxygenation membranes which 
allow for gas exchange and visibility; the 3D inner core is a fiber-based matrix composed of an inert and biocom-
patible synthetic polyester. The matrix has a thickness of 400 μm and its empty volume represents approximately 
90% of the entire volume. Internally, VITVO consists of two chambers separated only by the 3D matrix (Fig. 1b). 
Each chamber has a port acting as an inlet or outlet depending on the media flow; the liquid enters the first 
chamber and then fills the second chamber passing through the 3D structure. Thus, the 3D matrix acts as a filter 
allowing cell retainment and the subsequent colonization of both fibers and the empty volume between (Fig. 1c). 
Cell suspension can be injected in VITVO with a syringe connected to the inlet port (Video). After loading, cells 
may be directly viewed under a fluorescence microscope and cellular growth can be monitored and quantified 
using either luminescence or fluorescence with a plate reader. In addition, due to the closed system design, the 
device can be shipped from the loading laboratory to the read-out laboratory where 3D cultures can be monitored 
in real-time and processed for histological analyses (Fig. 1d and Supplementary Fig. 1).
Figure 1. VITVO technology and potentials. (a) Picture of the VITVO platform. (b) VITVO cartoon section 
showing structure and parts. (c) VITVO loading of cell suspension with a syringe allows colonization of the 
3D matrix inner core. (d) Cells can be directly visualized in VITVO under a fluorescence microscope; cellular 
viability and growth can be monitored using luminescence or fluorescence with a plate reader instrument; 
VITVO system is closed, thus the device is easily transported and can be shipped; methacrylate embedding of 
3D tissue rebuilt in VITVO allows histological studies on tissue slices.
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VITVO is biocompatible and allows real-time monitoring of 3D tumor cell growth. Several 
tumor cell lines derived from different histotypes were introduced to assess VITVO biocompatibility and its 
capacity to support high-density 3D cell growth. To directly visualize cells using fluorescence microscopy, the cell 
lines were gene-modified to stably express two fluorescent proteins (dsRED: red and GFP: green). Ewing sarcoma 
(A673 dsRED+), glioblastoma (U87MG dsRED+), breast cancer (Bt549 GFP+), and pancreatic (BxPC3 GFP+) 
tumor cell lines were then loaded in VITVO and their growth was monitored for up to 96 hours after seeding 
(Fig. 2). The progressive 3D matrix colonization by labeled proliferating cells was directly monitored under a 
fluorescence microscope (Fig. 2a). The 3D matrix alone with culture media did not have any autofluorescence in 
both GFP and RFP channels (not shown).
Figure 2. Cell growth in VITVO. (a) In VITVO tumor growth monitoring under a fluorescence microscope. 
Scale bar 1,000 μm. (b) In VITVO cell viability monitoring using Real Time GLO (Promega). Real Time GLO 
was added at 1X concentration at seeding, at 24 h and 48 h for A673 dsRED, U87MG dsRED and Bt549 GFP, 
while it was added at 2X concentration for the 72 h and 96 h time points. For BxPC3 GFP, Real Time GLO was 
added 1X concentration at seeding and at 24 h, and 2X concentration at 48 h/72 h/96 h. All measurements were 
performed in triplicate and data are expressed as means ± standard deviation (SD) (c) Estimation of tumor cells 
number in VITVO based on relative light units (RLU; cell number = measured RLU*cell number at seeding/
RLU at seeding).
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To further confirm the data and generate quantitative measures, the number of living cells inside VITVO for 
each cell line was then evaluated using the Real Time-Glo MT cell viability assay with a luminometer, as an addi-
tional applicable read-out in combination with the microscopy.
The addition of Real Time-Glo reagent in culture media produce a bioluminescence signal proportional to the 
number of viable cells. Cells loaded in VITVO and incubated with Real Time-Glo generated a gradual increase in 
bioluminescence signal, thus indicating viable cells progressively proliferate and colonize the 3D matrix (Fig. 2b).
Using this assay, cell growth could be directly monitored over time inside the system by measuring the relative 
light units (RLU). Considering the number of cells (5.6 × 105 cells/device) initially loaded into the VITVO system 
and using RLU values at each time point, estimating the number of cells inside the system up to 96 hours was 
possible (Fig. 2c).
These findings indicate VITVO is biocompatible and can sustain a 3D cell growth in a variety of cancer types 
which can be monitored using both microscopy and luminometry.
VITVO supports 3D cytotoxicity assay. After observing the capacity of VITVO to provide a 3D support 
for cancer cell line proliferation, the use of the system as a tool to monitor the impact of a known chemotherapy 
agent against a selected cell line was investigated.
Thus, the pancreatic tumor cell line BxPC3 expressing GFP was loaded in VITVO and 24 hours after the 
seeding, cells were treated with nab-paclitaxel (nab-PTX) (Fig. 3). Tumor cell viability was regularly monitored 
using both microscopy and Real Time-Glo assay. A reduction of GFP+ cell density was clearly observed under 
fluorescence microscope 24 hours after adding the drug. In treated samples, the cytostatic action of nab-PTX 
markedly affected the tumor cell growth compared with untreated controls where BxPC3 progressively colonized 
VITVO (Fig. 3a).
At 48 hours, this observation was further confirmed with a significant reduction of the green signal. Cell 
growth was additionally monitored using the cell viability assay and after 48 hours of nab-PTX treatment, a sig-
nificative reduction of cell viability (RLU) was observed in treated samples compared with untreated controls 
(Fig. 3b), confirming the data of the microscopic evaluations and suggesting that VITVO is a suitable tool for 
testing cytotoxicity at different time points and with distinct read-outs.
VITVO hosts a biologic-agent driven pro-apoptotic effect visible using the luciferase assay. 
Starting with the cytotoxicity generated by a chemotherapy agent in VITVO, the system was further tested 
using a pro-apoptotic biologic agent, the soluble form of TNF-related apoptosis-inducing ligand (sTRAIL)15. 
Figure 3. In VITVO efficacy evaluation of a chemotherapy agent. (a) In VITVO visualization of GFP+ BxPC3 
under a fluorescence microscope. Scale bar 100 μm. (b) In VITVO growth monitoring of tumor cells after 
treatment with 500 nM nab-PTX using Real Time GLO viability assay. Untreated cells were used as control. All 
measurements were performed in triplicate and data expressed as means ± SD, *P = 0.015 (t-test).
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sTRAIL induces tumor cell death by interacting with specific receptors; this event triggers intracellular sig-
nals that ultimately activate caspases which induce apoptosis. In addition, decoy receptors can interfere with 
the mechanism of action16. Moreover, sTRAIL has a relevant molecular weight (at least 36 KDa) significantly 
higher than a chemical compound, possibly interfering with its biodistribution and penetration in a 3D struc-
ture. Considering the complexity of the mechanism that induces apoptosis and accounting for the 3D structure, 
sTRAIL in VITVO was tested against an Ewing sarcoma cell line with in vitro and in vivo TRAIL sensitivity17. 
Two different bioluminescent-based approaches were compared; in addition to the Real Time-Glo assay applied 
to gene-engineered dsRED positive A673 cell line (dsRED+ A673), a second dsRED negative A673 (dsRED− 
A673) cell line variant expressing luciferase (Luc+ A673), which is typically used in in vivo xenotransplants, was 
generated.
DsRed+ A673 or Luc+ A673 cells were then loaded in VITVO and grown for 72 hours to repopulate the 3D 
matrix and obtain a consistent tumor bulk. dsRED+ A673 growth was monitored using fluorescence microscopy 
(Fig. 4a), confirming that VITVO can support sarcoma 3D proliferation. When sTRAIL treatment was started, 
the pro-apoptotic effect was clearly visible with a reduction of red fluorescence at 24 hours, indicating the rele-
vant anti-sarcoma effect was triggered by sTRAIL (Fig. 4b). The data were then confirmed using Real Time-Glo 
Figure 4. In VITVO evaluation of sTRAIL pro-apoptotic action on Ewing sarcoma using two different 
luminometric approaches. (a) In VITVO dsRED+ A673 visualization using fluorescence microscopy at 
seeding and after 72 hours. Scale bar 100 μm. (b) In VITVO monitoring of sTRAIL action against tumor 
using microscope visualization of fluorescent cells during treatment (0 hour and 24 hours). (c) In VITVO 
measurement of dsRED+ A673 viability based on RealTime-Glo. Cell growth was monitored for 72 hours (left 
panel), then sTRAIL was added in VITVO and cell viability was measured after 24 hours based on luminescence 
(right panel). Untreated dsRED+ A673 cells were used as control. All measurements were performed in 
triplicate and data are expressed as means ± SD *P = 0.003. (d) In VITVO measurement of Luc+ A673 viability 
by the addition of luciferin. Cell growth was monitored for 72 hours (left panel), then sTRAIL was added in 
VITVO and cell viability was measured after 24 hours based on luminescence (right panel). Untreated Luc+ 
A673 cells were used as control. All measurements were performed in triplicate and data are expressed as 
means ± SD, *P = 0.002.
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assay which showed the rapid VITVO repopulating activity of dsRED+ A673 cells (Fig. 4c, left panel), as well 
as the capacity of sTRAIL to significantly reduce the number of living cells in 24 hours (Fig. 4c, right panel). 
Simultaneously, the performance of Luc+ A673 cells was evaluated by adding the luciferin substrate into the 
culture and measuring the RLU caused by luciferase activity. The luciferase assay confirmed VITVO can host the 
rapidly growing Ewing sarcoma cell line (Fig. 4d, left panel), further demonstrating the assay can prove cell death 
with comparable results between the two luminometric readouts (Fig. 4d, right panel).
Thus, VITVO can be used to explore the anti-cancer potential of biologic agents in 3D and the addition of 
luciferase in target cells is suitable for comparative studies that may also involve parallel in vivo investigations.
VITVO can be loaded with primary lung cancer cells targeted by nivolumab to rapidly identify 
an immune-based anti-tumor response. Based on the results obtained using VITVO against tumor 
cell lines, whether the system could also host human primary tumor cells together with their accessory cells was 
investigate, as prerequisite before introducing the device as a predictive tool in oncology. Specifically, in addition 
to histological assessment of PD1-PDL1, the focus was on immuno-oncology agents, since rapid functional tests 
that can predict the efficacy of checkpoint inhibitors are lacking18.
Therefore, the use of VITVO for evaluating the efficacy of nivolumab in promoting anti-tumor immunity 
of tumor-infiltrating lymphocytes (TILs) in non-small-cell lung cancer (NSCLC) was investigated following 
the experimental scheme shown in Fig. 5a. After obtaining approved informed consent, NSCLC specimens 
were obtained from chest surgery patients and tumor cells were dissociated using a semi-automated combined 
mechanical/enzymatic process. Digested cells were first evaluated using fluorescence-activated cell sorting 
(FACS) to identify and quantify TILs (Fig. 5b) and unfractionated cells (2 × 106) were loaded in VITVO with 40 
μg/mL of nivolumab; untreated cells were used as control. Real Time-Glo was then added to monitor cell viability 
measured at seeding and after 24 hours. As shown in Fig. 5c, the viability of treated samples was dramatically 
compromised compared with the untreated samples, suggesting a possible trigger of anti-tumor activity of cyto-
toxic TILs by nivolumab.
In addition to the Real Time-Glo to visualize tumor cell death in the matrix using microscopy, another assay 
that can discriminate between living (green) and dying cells (red; Fig. 5d) was used. The fluorescence-based Live/
Dead assay was performed over a longer time period (48 hours) showing a significant increase of red-colored 
cells in nivolumab-treated samples and confirmed the results obtained using the bioluminescence approach. 
Collectively, these results indicate a proof of concept in which VITVO can host primary tumor cells harvested 
from a tumor specimen to be rapidly (<48 hours) introduced in a functional assay for cancer responsiveness to 
checkpoint inhibitors.
In VITVO dose finding study for a gene therapy-based approach. During the development 
of cell-based approaches in cancer, a major limitation is identification of the proper cell dose that should be 
associated with the desired therapeutic outcome (https://www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM564952.pdf).
The progressive introduction of cancer cell therapies into the clinic, in addition to animal models that may 
be limited in hosting human cancers18, should require in vitro tools that can mimic the clinical setting in which 
cell growth can influence molecular biomarkers and antigenic profiles19–22. Therefore, whether a 3D system 
such as VITVO may have value in simultaneously hosting target and effector cells and identifying the effec-
tive dose compared with the dose determined in an animal study was investigated. Thus, luciferase-positive 
pancreatic adenocarcinoma cells (Luc+ BxPC-3) were loaded in VITVO repopulating the 3D inner core; after 
24 hours, adipose-derived mesenchymal stromal cells (AD-MSCs), genetically modified to secrete soluble TRAIL 
(MSC-sTRAIL)23, were injected in VITVO at different effector:target ratios (E:T 1:10 and 1:30). Then, luciferin 
was added to the system to evaluate cell viability at different time points by measuring RLU.
After 24 hours of 3D co-culture with MSC-sTRAIL and Luc+ BxPC-3, both doses were found effective against 
pancreatic adenocarcinoma cells. However, at a longer observation time point (48 hours and 72 hours), the lowest 
ratio (1:30) of cells did not control tumor growth while the highest ratio (1:10) maintained a statistically signifi-
cant reduction in tumor bulk compared with control (Fig. 6a).
To assess the VITVO potential in this context, the obtained VITVO results were compared with those gen-
erated by an in vivo subcutaneous xenotransplant model (Fig. 6b). After subcutaneous injection of BxPC-3 
(2 × 106), mice were divided into three groups (n = 6 mice per group): control (no treatment), E:T 1:10 (E: 
4 × 106), and E:T 1:30 (E: 1.3 × 106). A single intratumoral injection of AD-MSC sTRAIL in subcutaneous pan-
creatic tumors was administered 15 days after BxPC-3 subcutaneous implantation. Tumor mass growth was mon-
itored during the experiment, and after 28 days, a statistically significative reduction in tumor volume compared 
with untreated group was observed only in the E:T 1:10 group. This result is in agreement with the in VITVO 
results and indicates dose-finding studies using in VITVO as a complementary tool for anti-cancer drug discov-
ery can be performed.
Discussion
Cell culture models are fundamental instruments for basic to translational research, in particular for cancer24,25. 
Although in vitro conditions do not exactly replicate in vivo situations, their role remains important3. Conversely, 
while in vivo data are critical in drug discovery, a comprehensive survey of drug screening tests has shown that 
approximately half of toxicological data derived from experiments with rodents does not correlate with the results 
from human trials26. Moreover, pre-clinical toxicity studies with multiple animal species may be poorly predic-
tive, and in several cases, drugs have failed during clinical trials in humans due to unexpected adverse toxici-
ties27,28. Therefore, development of new in vitro models that can mimic the in vivo complexity and in combination 
with reliable animal models are needed to overcome these issues.
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3D tissue cultures are fast emerging tools to better investigate cell biology and improve the clinical relevance 
of culturing cells outside a living body29,30. Based on bioreactor technology and considering these unmet needs, 
we developed VITVO as an innovative 3D tool providing a tissue-sized platform where cells can recreate their 
environment with a higher level of complexity and in a simple manner.
Figure 5. In VITVO testing of the effect of nivolumab on lung primary tumor. (a) Experimental scheme. 
(b) Immunostaining of unfractionated tumor cells dissociated from lung cancer specimen with anti-CD3, 
anti-CD4, and anti-CD8 to quantify the percentage of immune cells (CD3+) and the cell subpopulations of 
lymphocyte T helper (CD4+) and lymphocyte T cytotoxic (CD8+). (c) In VITVO cell viability evaluation based 
on RealTime-Glo at seeding and after 24 hours of treatment with nivolumab. Real Time GLO was used at a 1X 
final concentration for both measurements. Untreated samples were used as control. All measurements were 
performed in triplicate and data are expressed as means ± SD, *P = 0.01. (d) In VITVO live and dead staining 
after nivolumab treatment (48 hours) to visualize live (green) and dead (red) cells. Representative images of 
untreated sample (left pic) and treated sample (right pic) are shown. Scale bar 1,000 μm.
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Focusing on experimental oncology, the VITVO flexibility allowed testing of several approaches with a variety 
of read-outs. Conventional assays developed to study biological function and for testing anti-tumor pharmaco-
dynamics are generally performed using 2D monolayer cultures; however, limits in predictability of the in vivo 
outcomes are well documented1,2. Therefore, 3D cancer cell cultures are expected to better mimic in vivo microen-
vironments, providing an improved understanding of their morphological and functional peculiarities21,22.
The miniaturization of both 2D and 3D cultures facilitated high throughput screening (HTS) technology, 
allowing the possibility to screen a large number of compounds evaluating the efficacy of a single endpoint9. 
However, this approach may not be completely predictive of the compound response in vivo, thus generating 
a high attrition rate in downstream drug development pipelines31. The gap between in vitro and in vivo may be 
bridged by creating more reliable assays for HTS or conceiving breakthrough technology based on low through-
put screening (LTS) that can generate high value data with an increased level of prediction. In miniaturized 3D 
system, such as spheroids, the floating cells form self-assembly aggregates in which some zones are not equally 
exposed to the environment changes (nutrients, gas and waste), impacting in the proper formation/performance 
of the tissue. This is particularly true for larger spheroids commonly presenting a concentrically layered structure 
with an internal apoptotic/necrotic core surrounded by a viable layer of quiescent cells and an external edge of 
proliferating cells. This situation may represent a limitation that often clashes with the possibility to obtain uni-
form structures able to mimic complexity and ensure reproducibility32. VITVO is a valuable tool to host a higher 
number of cells recreating a critical tumor mass with the possibility to generate an increased level of complexity 
by co-culturing different cell types and better mimic an in vivo microenvironment within a defined morphometry 
due to the shape of the inner core of the 3D system. As reported for other 3D cultures on scaffold32,33, VITVO 
is limited in the direct measurement of tumor size reduction after treatment, however it assesses cell viability in 
Figure 6. In VITVO dose finding for cell-based therapy. (a) In VITVO cell viability of Luc+BxPC3 was 
evaluated by the addition of luciferin after treatment with MSC-sTRAIL at different effector:tumor ratios 
(E:T 1:10 and 1:30) at 24-, 48-, and 72-hour time points. Untreated Luc+ BxPC3 cells were used as control. All 
measurements were performed in triplicate and data are expressed as means ± SD. *P = 0.000003, **P = 0.0004, 
***P = 0.007, #P = 0.004, ##P = 0.004, ¶P = 0,015, ¶¶P = 0.0006, based on ANOVA and multiple comparisons. 
(b) In vivo xenotransplant of BxPC3 and evaluation of tumor inhibition by a single subcutaneous intratumoral 
injection of MSC-sTRAIL at different effector:tumor ratios (E:T 1:10 and 1:30). Untreated mice were used as 
control. Values are expressed as means ± SEM; *P = 0,04 based on ANOVA and multiple comparisons.
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comparison to controls similarly to what is done when luciferase assay is performed in vivo. In that case, even if 
tumor size and residual cell number are not directly measured, the number of photons correlates with the reduc-
tion of tumor size and viable cells. Being aware of this limitation and in the attempt to overcome it, VITVO can 
be processed for histology where tumor mass can be also visualized for more direct histomorphological measure-
ments (Supplementary Fig. 1).
Therefore, the system can be used in LTS strategies and the platform was validated using different types of 
cancer cells including mesenchymal, epithelial, and neuroectodermal tumors. Based on the data, the device can 
host various cell types that can be loaded into the device, repopulate the matrix, and survive in the closed environ-
ment due to the gas permeable membranes. Cell cultures were usually performed at 37 °C with 5% CO2, however, 
growing tumor cells in VITVO outside the incubator at 37 °C (for at least 48 hours) was achieved (Supplementary 
Fig. 2). In addition, the possibility to load a mix of different cells types originating either from freshly digested 
tumor samples or established cells lines (i.e. MSC and tumors) was demonstrated. Consequently, potential appli-
cations in which VITVO can be used to study the interactions between tumors and the different cells in their 
microenvironments (lymphocyte-subsets, myeloid derived cells, stroma, and endothelium), without limiting the 
number and type of cells, can be developed. Importantly, the flat nature of the system allows the monitoring of 3D 
matrix colonization and interaction due to cell labeling visible using microscopy and plate readers utilizing both 
fluorescence and luminescence. Finally, the structure enables the specific cancer niches to remain stable in the 3D 
matrix, allowing to follow them using microscopy without the risk of movement that could impair identification 
during the experimental period.
All these factors are relevant for better understanding the dynamic interactions of a tumor and rebuilding its 
environment in VITVO for metabolic, immuno-oncology and basic genomic investigations. By sampling the 
media, soluble factors released during interactions can be tested and DNA/RNA can be obtained from the cells 
repopulating the matrix using commercially available kits directly within the system for immediate use or storage 
(Supplementary Fig. 3).
The simplicity of use and the adaptability to the common laboratory equipment may allow a rapid transfer of 
the technology into both academic and pharmaceutical research and development fields. Due to the closed sys-
tem design, VITVO additionally offers the advantage of transportability; the tumor sample can be loaded at the 
clinical facility and then shipped to a remote laboratory for the necessary tests.
All these values contribute to build a 3 V concept: in vitro, in VITVO and in vivo. In vitro HTS provides the 
identification of new drug candidates; in VITVO testing can reveal pharmacodynamics and efficacy dose ranges 
of these compounds using primary and/or established cell line in 3D, to then proceed in vivo with more relevant 
information, ultimately reducing the number of animal investigations with a significant lowering in the attrition 
rate of drug development.
An additional relevant application of the VITVO system is in the field of immuno-oncology having value both 
in drug development and clinical settings, where rapid functional tests allowing prediction of patient response are 
still lacking9. In the present study, freshly isolated cells collected from lung cancer patients and loaded in VITVO 
without the addition of effector cells, elicited the TIL activation caused by nivolumab against tumor cells. To the 
best of our knowledge, this process has not been previously described and presumably, the 3D growth generates 
favorable cell-to-cell interactions playing a key role in obtaining a closer relationship between target and effectors, 
as observed in patients. Subsequently, an anti-tumor response is generated due to anti-PD1 antibodies and for 
better tumor antigen expression caused by 3D cell growth, as previously reported21,22.
In conclusion, a novel device for 3D cell culture was introduced in the present study. The simplicity of use and 
readout flexibility of VITVO allows a variety of pre-clinical investigations in oncology, with a possible relevant 
impact in other areas, such as toxicology studies using hepatocytes and for other more complex toxicology assays 
using inducible progenitors.
Methods
VITVO loading and 3D cell culture establishment. VITVO was first primed with media alone to 
ensure the complete wetting of 3D matrix. Next, 5.6 × 105 cells were suspended in 1.4 mL of culture media and 
injected into the system with a 5 mL syringe (Becton Dickinson and Co, Franklin Lakes, NJ, USA). For each cell 
type, culture media were changed every 24 hours.
Tumor cell lines. The following tumor cell lines were purchased from ATCC (LGC Standards srl, Milan, 
Italy) and genetically modified by viral infection to express fluorescent protein: Retroviral vectors MSCV-GFP 
and MSCV-dsRED were transiently transfected into 293 T cells together with a mixture of helper plasmid accord-
ing to the jetPEI protocol (Cell Signaling Technology Inc., Danvers, MA, USA). After 48 hours, conditioned 
media containing retroviral particles were collected to stably transduce FLYRD18 packaging cell line for the 
continuous production of viral particles. FLYRD18-conditioned media were used to perform 3 hits of infection 
on tumor cell lines (6 hours of incubation/day).
Ewing sarcoma A673 was modified to express dsRED protein, pancreatic adenocarcinoma BxPC3 modified to 
express GFP protein, glioblastoma U87MG modified to express dsRED protein, and breast cancer Bt549 modified 
to express GFP protein.
Luciferase-positive BxPC3 was obtained using lentiviral particles purchased from Perkin Elmer (Waltham, 
MA, USA).
A673 and U87MG were cultivated in Iscove (Euroclone, Padmington, UK), and BxPC3 and Bt549 were seeded 
in RPMI-1640 (Thermo Fisher Scientific, Waltham, MA, USA).
Media were supplemented with 10% fetal bovine serum (FBS, PAA, Pasching, Austria), 1% glutamine 
(200 mM), and 1% penicillin‐streptomycin (104 UI/mL and 10 mg/mL; both from Euroclone).
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In VITVO observation using fluorescence microscopy. Cells in VITVO were directly visualized with 
an EVOS FL auto (Thermo Fisher Scientific) using GFP and RFP LED cubes and/or an Axiovert 200 M fluores-
cence inverted microscope (Zeiss, Oberkochen, Germany).
In VITVO growth monitoring using luminescence. Cell growth evaluation was performed using the 
Real Time-Glo MT cell viability assay (Promega, Madison, WI, USA) with a protocol specifically developed for 
VITVO. This protocol was designed to ensure sufficient quantity of reagent considering the enlarged model com-
pared with the miniaturized system. Real Time-Glo was added to the cells immediately before the cell load-
ing in VITVO at a final 1X concentration. After incubation, Relative Light Units (RLU) were measured using a 
luminometer (GloMax Discover System, Promega). The reagent was re-added at each change of media (1X or 
2X final concentration), depending on the cell type and considering the size and growth rate. 2X concentration 
allows having enough quantity of substrate for high number of cells in culture, however the emitted signal (RLU) 
remains directly proportional to the number of viable cells. Thus, the substrate has not been considered a limiting 
factor even at lower concentration (Supplementary Fig. 4). After incubation, RLU were remeasured using the 
luminometer. Since RLU value is directly proportional to the number of viable cells and knowing the number of 
cells at seeding and the corresponding RLU value, the number of cells in VITVO was estimated using the meas-
ured RLU at each time point.
RLU were measured directly from VITVO using a tray and setting the instrument (GloMax Discover System, 
Promega) to read the two central wells of a 6 multi-well plate. Viability of luciferase-positive cells loaded in 
VITVO was evaluated by adding the substrate luciferin (Promega) into culture and measuring RLU.
Drugs and treatments in VITVO. For testing Nab-paclitaxel (Abraxane, Celgene, Milan, Italy), sTRAIL, 
and MSC-sTRAIL were used at the specified concentrations and added in VITVO within the culture media as a 
single dose.
Primary cells from human lung cancer. The study was approved by the Ethical and Institutional 
Review Board of the University Hospital of Modena and was performed in accordance with the relevant 
guidelines and regulations. Tumor specimens were obtained after obtaining signed informed consent from 
patients who underwent surgery at the Chest Surgery Division (University Hospital of Modena). Tumor tis-
sues were dissociated into single cells using the Human Tumor Dissociation Kit (MACS, Miltenyi Biotec, 
Bergisch Gladbach, Germany) with GentleMACS Octo Dissociators and heater protocols (Miltenyi Biotec). 
Immunophenotyping of cells recovered after tumor tissue digestion was performed. Cells were counted, 
seeded in FACS analysis polypropylene tubes (1 × 106/tube; VWR, Milan, Italy) and incubated in blocking 
buffer (100 μL each 1 × 106 MSC) containing Dulbecco’ s modified Eagle medium (DMEM), 10% FBS, 0.1 M 
sodium azide, and 66.6 mg/mL human immunoglobulin G (Sigma, Steinheim, Germany) for 20 minutes on 
ice. Cells were subsequently stained for 30 minutes on ice with primary antibodies in PBS with 0.1% bovine 
serum albumin (BSA; Sigma) and analyzed using a FACS ARIA III (BD Bioscience, Franklin Lakes, NJ, USA). 
The following monoclonal antibodies were used: CD3-PE, CD-8-APC, CD4-FITC; 7-amino-actinomycin-D 
(7AAD)-staining (ViaProbe; BD Biosciences; 20 μL/1 × 106 cells, according to the manufacturer’ s instruc-
tions) and evaluated using flow cytometry to detect apoptosis.
Primary cells were plated in RPMI-1640 (Thermo Fisher Scientific), supplemented with 10% FBS (PAA), 1% 
glutamine (200 mM), and 1% penicillin‐streptomycin (104 UI/mL and 10 mg/mL; both from Euroclone).
In vivo dose finding. All animal experiments were approved by the Animal Ethics Committee of Modena 
and all methods were performed in accordance with the relevant guidelines and regulations. Tumor implantation 
and cell delivery were performed as described in the Results section.
NOD.CB17-Prkdcscid/NCrCrl mice were purchased from Charles River (Wilmington, MA, USA).
Statistics. Data were analyzed using Microsoft Excel 2016 (Microsoft Corporation) and expressed as mean 
values ± standard deviation (SD) or ± standard error of the mean (SEM). Unpaired two-tailed Student’s t-test 
was used and a p-value ≤ 0.05 was considered statistically significant. ANOVA test was performed using Prism 
software (GraphPad 8 Software Inc., La Jolla, CA, USA).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author upon reasonable request.
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